Niagen Bioscience, Inc. Cash Flow Statement
NAGE|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Niagen Bioscience, Inc. generated $14M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $17.4M | -$4.9M | -$16.5M | -$27.1M | -$19.9M | -$32.1M | -$32.1M | -$11.4M | -$11.4M | -$2.9M | -$2.8M | -$5.4M | -$11.7M | -$7.9M | -$2.1M |
| Depreciation & Amortization | - | $870.0K | $869.0K | $890.0K | $871.0K | $762.0K | - | $510.0K | $510.0K | $332.0K | $286.0K | $223.0K | $328.1K | $328.6K | $313.8K |
| Operating Cash Flow | $13.5M | $7.1M | -$15.1M | -$24.2M | -$10.6M | -$20.4M | -$20.4M | -$9.8M | -$9.8M | -$2.9M | -$2.1M | -$2.6M | -$10.1M | -$4.1M | -$2.7M |
| Capital Expenditures | - | - | - | - | - | - | $743.0K | $1.2M | $1.2M | $1.5M | $525.2K | $123.1K | $24.6K | $150.7K | $169.1K |
| Free Cash Flow | - | - | - | - | - | - | -$21.2M | -$11.0M | -$11.0M | -$4.4M | -$2.6M | -$2.7M | -$10.1M | -$4.2M | -$2.8M |
| Share Buybacks | $251.0K | - | - | - | - | - | - | $0 | $0 | - | - | - | -$8.2K | $8.2K | - |
| FCF Margin | - | - | - | - | - | - | -45.8% | -51.7% | -51.7% | -20.5% | -14.7% | -17.6% | -87.4% | -52.4% | -37.4% |